Relmada Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Relmada Therapeutics

19/03/2024 21:02

* Relmada Therapeutics Inc  RLMD.OQ  reported a quarterly
adjusted
loss of 84 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-1.41.  The mean expectation of five analysts
for the quarter was for a loss of 83 cents per share. Wall
Street expected results to range from -91 cents to -74 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Relmada Therapeutics Inc's reported EPS for the quarter
was a
loss of 84 cents​.
    * The company reported a quarterly loss of $25.17 million.
    * Relmada Therapeutics Inc shares had risen by 33.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Relmada
Therapeutics Inc is $6.75 
This summary was machine generated from LSEG data March 19 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.83          -0.84          Missed
 Sep. 30 2023      -0.91          -0.73          Beat
 Jun. 30 2023      -0.90          -0.84          Beat
 Mar. 31 2023      -0.89          -0.87          Beat